Physician profile

Lalitha Anand

Hematology & Oncology · Berkeley Heights, NJ

NPI 1285948380

$495.88

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

See the full distribution for Hematology & Oncology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$29.08
Food and Beverage$14.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $197.99 2019
Astellas Pharma US INC $95.00 2020
Alexion Pharmaceuticals, INC. $77.00 2019
Seagen INC. $60.07 2020-2021
Janssen Pharmaceuticals, INC $29.08 2024 Xarelto
Novartis Pharmaceuticals Corporation $22.68 2021
Celgene Corporation $14.06 2023 Reblozyl

4 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lalitha Anand

$495.88

in general payments reported 2019-2025

Years
2019-2024
Top company
Amgen INC.

https://glasscript.com/doctor/1300651/lalitha-anand

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.